Clinical manifestations and cardiovascular complications of Raynaud's syndrome
PDF

Palavras-chave

Doenças Crônicas não Transmissíveis (DCNT), Cuidados Paliativos, Doenças degenerativas, Brasil.
Doenças cardiovasculares; Inovações terapêuticas; Inibidores de SGLT2 e Reposição de testosterona
Insuficiência cardíaca; Manifestações clínicas; Diagnóstico.
Doenças autoimunes
Vasoconstriction

Como Citar

Nojosa Oliveira, G., Ana Clara Linhares Volpp, Luis Felipe Amaral Bueno, Isabela Machado de Souza, Thaís Augusta Quirino Esteves, Thiago Mendonça Estrela Nascente, Camylla Silva Gomes Paulino, Rejayne Carvalho Branquinho, Luis Felipe Brito Beffart, Juliana Quirino da Silveira, Vinicius Trevisan Alves, & Izabella Trevisan Alves. (2024). Clinical manifestations and cardiovascular complications of Raynaud’s syndrome. Brazilian Journal of Implantology and Health Sciences, 6(9), 722–736. https://doi.org/10.36557/2674-8169.2024v6n9p722-736

Resumo

Introduction: Raynaud syndrome is a vasomotor disorder that predominantly affects the fingers of the hands and feet, characterized by episodes of pallor, cyanosis and flushing due to changes in blood circulation. These manifestations occur in response to stimuli such as cold or emotional stress, leading to temporary constriction of peripheral blood vessels. Although often benign, the syndrome may be associated with various cardiovascular complications, especially when it occurs in secondary form, related to autoimmune conditions or connective tissue diseases. Understanding clinical manifestations and potential cardiovascular complications is crucial for proper management and more severe impact prevention on patients' cardiovascular health. Objective: To examine clinical manifestations and cardiovascular complications associated with Raynaud syndrome, analyzing the prevalence, gravity and mechanisms involved in its clinical presentation. METHODOLOGY: For review, checklist prisma was used to ensure transparency and quality of the review. Pubmed, Scielo and Web of Science databases were consulted using five descriptors: “Raynaud syndrome”, “cardiovascular complications”, “clinical manifestations”, “peripheral vasoconstriction” and “autoimmune diseases”. Studies have been included published in the last 10 years. The inclusion criteria were: studies that directly addressed cardiovascular complications of Raynaud syndrome, pairs revised articles and research with original clinical data. The exclusion criteria were: articles outside the established period, case studies not related to cardiovascular complications and articles not available in full text. RESULTS: Review revealed that clinical manifestations of Raynaud syndrome include cyclic changes in extremity coloration and symptoms of pain or discomfort in vasoconstriction phases. Identified cardiovascular complications include pulmonary hypertension and increased risk of peripheral arterial diseases. Studies also indicated an association with autoimmune diseases such as scleroderma, where the severity of symptoms and cardiovascular complications can be accentuated. Conclusion: Raynaud syndrome, in addition to its typical clinical manifestations, is associated with various cardiovascular complications that can significantly impact the patient's health. Early recognition and proper management of these complications are essential for improving the quality of life and preventing more serious adverse events. Integration of adequate clinical and therapeutic approaches can reduce risk and improve long -term results for affected individuals.

https://doi.org/10.36557/2674-8169.2024v6n9p722-736
PDF

Referências

Joven BE, Carreira PE. Síndrome de Raynaud: etiología y manejo. Reumatol Clin. 2008;4(2):59-66. doi:10.1016/S1699-258X(08)71801-1

Faro M, Sàez-Francás N, Castro-Marrero J, Aliste L, Fernández de Sevilla T, Alegre J. Gender differences in chronic fatigue syndrome. Reumatol Clin. 2016;12(2):72-77. doi:10.1016/j.reuma.2015.05.007

Cornudella Lema J, Sánchez-González B, Carrión-Barberà I, Vázquez Montes de Oca S, García Pallarols F, Salman-Monte TC. Immune thrombocytopenia in systemic lupus erythematosus: Prevalence, risk factors, and a novel predictive model for risk assessment. Med Clin (Barc). 2024;162(10):461-469. doi:10.1016/j.medcli.2023.12.012

González-Huezo MS, Delgado-Ayala LY, Osorio-Núñez AL, Meléndez-Mercado C. Autoimmune associations in a Mexican cohort with primary biliary cholangitis. Asociaciones autoinmunes en una cohorte mexicana con colangitis biliar primaria. Rev Gastroenterol Mex (Engl Ed). 2019;84(2):130-135. doi:10.1016/j.rgmx.2018.03.008

Pauling JD, Hughes M, Pope JE. Raynaud's phenomenon-an update on diagnosis, classification and management. Clin Rheumatol. 2019;38(12):3317-3330. doi:10.1007/s10067-019-04745-5

Temprano KK. A Review of Raynaud's Disease. Mo Med. 2016;113(2):123-126.

Choi E, Henkin S. Raynaud's phenomenon and related vasospastic disorders. Vasc Med. 2021;26(1):56-70. doi:10.1177/1358863X20983455

Fábián B, Csiki Z. Raynaud-szindróma, 2024 [Raynaud's syndrome, 2024]. Orv Hetil. 2024;165(17):643-651. Published 2024 Apr 28. doi:10.1556/650.2024.33026

Kadian-Dodov D. Cold Hands or Feet: Is It Raynaud's or Not?. Med Clin North Am. 2023;107(5):829-844. doi:10.1016/j.mcna.2023.04.005

Ramahi A, Hughes M, Khanna D. Practical management of Raynaud's phenomenon - a primer for practicing physicians. Curr Opin Rheumatol. 2022;34(4):235-244. doi:10.1097/BOR.0000000000000877

Prete M, Fatone MC, Favoino E, Perosa F. Raynaud's phenomenon: from molecular pathogenesis to therapy. Autoimmun Rev. 2014;13(6):655-667. doi:10.1016/j.autrev.2013.12.001

Cutolo M, Smith V, Furst DE, Khanna D, Herrick AL. Points to consider-Raynaud's phenomenon in systemic sclerosis. Rheumatology (Oxford). 2017;56(suppl_5):v45-v48. doi:10.1093/rheumatology/kex199

LeRoy EC, Medsger TA Jr. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol. 1992;10(5):485-488.

Herrick AL. Therapeutic implications from the pathogenesis of Raynaud's phenomenon. Expert Rev Clin Immunol. 2017;13(7):723-735. doi:10.1080/1744666X.2017.1279052

Curtiss P, Svigos K, Schwager Z, Lo Sicco K, Franks AG Jr. Part II: The treatment of primary and secondary Raynaud's phenomenon. J Am Acad Dermatol. 2024;90(2):237-248. doi:10.1016/j.jaad.2022.05.067

Cardelli MB, Kleinsmith DM. Raynaud's phenomenon and disease. Med Clin North Am. 1989;73(5):1127-1141. doi:10.1016/s0025-7125(16)30623-x.

Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.

Copyright (c) 2024 Gabriel Nojosa Oliveira, Ana Clara Linhares Volpp, Luis Felipe Amaral Bueno, Isabela Machado de Souza, Thaís Augusta Quirino Esteves, Thiago Mendonça Estrela Nascente, Camylla Silva Gomes Paulino, Rejayne Carvalho Branquinho, Luis Felipe Brito Beffart, Juliana Quirino da Silveira, Vinicius Trevisan Alves, Izabella Trevisan Alves